Compare McKesson Corporation (MCK) vs Strategy Inc. (MSTR) Price & Performance

McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.

The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.

MSTR trades at $151.89, down 0.96% on the day, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with a net income margin of -6,102.96% and three consecutive quarterly earnings misses. Despite negative profitability, analyst consensus remains bullish with a $253.36 price target, representing 67% upside potential from current levels. Recent news highlights Citigroup doubling its price target to $240 following a 35% monthly rally.

The outlook remains polarized between technical optimism and fundamental challenges. While technical indicators suggest continued momentum, the company's massive losses and negative cash flow from operations pose significant risks. Investors face the dilemma of strong Wall Street support against deteriorating financial performance, with the stock's fate closely tied to Bitcoin market movements despite being a traditional software company.